

Docket No.: PF-0502-1 DIV

"Express Mail" mailing label number EL 856 156 399 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on August 14, 2001.

By: Nancy Ramos Printed: Nancy Ramos

jc978 U.S. PTO  
09/930026  
08/14/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal, et al.

Title: NUCLEIC ACIDS ENCODING HUMAN UBIQUITIN-CONJUGATING  
ENZYME HOMOLOGS

Serial No.: To Be Assigned Filing Date: Herewith  
Examiner: To Be Assigned Group Art Unit: To Be Assigned

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 9325, filed 0134, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 14 August 2001

*for* Richard C. Elstner Reg. No. 37,027  
David G. Streeter, Ph.D.  
Reg. No. 43,168  
Direct Dial Telephone: (650) 845-5741

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.
	PF-0502-1 DIV	To Be Assigned
LIST OF REFERENCES CITED BY APPLICANTS	Applicant(s)	
(Use several sheets if necessary)	Lal et al.	
	Filing Date	Group
	To Be Assigned	To Be Assigned

## U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,744,343	04/28/98	Draetta et al.	435	193	
	2	5,976,837	11/2/99	Jacobs et al.	435	691	

## Foreign Patent Documents

							Translation	
		Document	Date	Country	Class	Subclass	Yes	No
	3	WO 98/40486	9/17/98	PCT			X	
	4	WO 98/45435	4/10/98	PCT			X	

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

5	Finley, D., et al., "Ubiquitination," <u>Annu. Rev. Cell. Biol.</u> , 7:25-69 (1991)
6	Scheffner, M., et al., "Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade," <u>Nature</u> , 373:81-83 (1995)
7	Nuber, U., et al., "Cloning of Human Ubiquitin-conjugating Enzymes Ubch6 and Ubch7 (E2-F1) and Characterization of Their Interaction with E6-AP and RSP5," <u>Journal of Biol. Chem.</u> , 271(5):2795-2800 (1996)
8	Scheffner, M., et al., "The HPV-16 E6 and E6-AP Complex Functions as a Ubiquitin-Protein Ligase in the Ubiquitination of p53," <u>Cell</u> , 75:495-505 (1993)
9	Prendergast, J.A., et al., "Increased Ubiquitin Expression Suppresses the Cell Cycle Defect Associated with the Yeast Ubiquitin Conjugating Enzyme, CDC34 (UBC3)," <u>Journal of Biol. Chem.</u> , 270(16):9347-9352 (1995)
10	Liu, Y., et al., "Intragenic Suppression among CDC34 (UBC3) Mutations Defines a Class of Ubiquitin-Conjugating Catalytic Domains," <u>Molecular and Cellular Biology</u> , 15(10):5635-5644 (1995)
11	Banerjee, A., et al., "Characterization of a Dominant Negative Mutant of the Cell Cycle Ubiquitin-conjugating Enzyme Cdc34," <u>Journal of Biol. Chem.</u> , 270(44):26209-26215 (1995)
12	Llovera, M., et al., "Muscle Wasting Associated with Cancer Cachexia is Linked to an Important Activation of the ATP-Dependent ubiquitin-Mediated Proteolysis," <u>Int. J. Cancer</u> , 61:138-141 (1995)
13	Attaix, D., et al., "Regulation of ATP-ubiquitin dependent proteolysis in muscle wasting," <u>Reprod. Nutr. Dev.</u> , 34:583-597 (1994)

Examiner

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation of not in conformance and not considered. Include copy of this form with your communication to applicant.